Press release
Pulmonary Fibrosis Market Projected to Reach USD 9.7 Billion by 2034
Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/71501
Between 2024 and 2034, the pulmonary fibrosis market is expected to expand steadily, fueled by advancements in antifibrotic therapies, increased research and development (R&D) in targeted biologics, and broader diagnostic adoption. Growing collaborations between biotech firms, healthcare institutions, and patient advocacy groups further underscore the sector's potential.
Market Overview
The global pulmonary fibrosis market size in 2024 is estimated at USD 5.2 billion and is projected to reach USD 9.7 billion by 2034, growing at a compound annual growth rate (CAGR) of 6.5% over the forecast period.
Key highlights include:
• Rising prevalence of idiopathic pulmonary fibrosis (IPF), the most common and severe form of the disease.
• Increasing adoption of antifibrotic drugs such as pirfenidone and nintedanib, which slow disease progression.
• Expanded clinical pipeline with biologics, gene therapies, and stem-cell-based treatments.
• High healthcare costs and delayed diagnosis remain major barriers.
• North America and Europe currently dominate the market, but Asia-Pacific is projected to witness the fastest growth by 2034.
Market Segmentation
By Product
• Antifibrotic Drugs (Pirfenidone, Nintedanib)
• Corticosteroids & Immunosuppressants
• Biologics & Monoclonal Antibodies
• Stem-Cell Therapies
• Others
By Technology
• Small Molecule Drugs
• Biologics (Monoclonal Antibodies, Recombinant Proteins)
• Gene Therapy & Regenerative Medicine
By Platform
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
By End Use
• Hospitals & Specialty Clinics
• Research & Academic Institutes
• Homecare Settings
By Application
• Idiopathic Pulmonary Fibrosis (IPF)
• Secondary Pulmonary Fibrosis (due to autoimmune diseases, occupational exposure, infections)
Summary of Segmentation
The antifibrotic drug segment remains dominant, owing to established usage of pirfenidone and nintedanib. However, biologics and regenerative therapies are gaining momentum, driven by promising results in clinical trials. Hospitals and specialty clinics account for the largest share, while online pharmacies are emerging as convenient distribution channels.
Explore Full Report here: https://exactitudeconsultancy.com/reports/71501/pulmonary-fibrosis-market
Regional Analysis
North America
• Largest revenue share in 2024 due to strong healthcare infrastructure, higher prevalence of IPF, and supportive reimbursement policies.
• Leading pharmaceutical companies and active clinical trial networks contribute significantly to market growth.
Europe
• Second-largest market with robust government support for rare disease research.
• Countries such as Germany, France, and the UK are key contributors, with patient registries and clinical trial participation on the rise.
Asia-Pacific
• Fastest-growing region during 2024-2034.
• Growth driven by rising awareness, increasing healthcare expenditure, and expanding clinical trial networks in China, India, and Japan.
• Local generic players are entering the antifibrotic drugs market, making treatments more affordable.
Middle East & Africa
• Gradual adoption due to limited awareness and lower diagnostic rates.
• Investment in tertiary healthcare and expansion of specialized treatment centers is expected to improve access.
Latin America
• Brazil and Mexico lead in regional adoption of therapies.
• Public healthcare system support for rare diseases is gradually increasing, but affordability remains a challenge.
Regional Summary
While North America and Europe dominate in terms of revenue, Asia-Pacific will shape the next phase of growth due to patient pool expansion, improving diagnostics, and cost-effective treatment availability.
Market Dynamics
Growth Drivers
• Rising global prevalence of pulmonary fibrosis, especially IPF, due to aging populations.
• Advances in antifibrotic and biologic therapies.
• Increasing healthcare spending and patient access programs.
• Supportive regulatory frameworks for orphan and rare disease drug approvals.
Key Challenges
• High treatment costs and limited reimbursement in developing nations.
• Late-stage diagnosis, leading to reduced treatment effectiveness.
• Safety concerns and side effects associated with long-term drug usage.
• Limited curative options-current therapies only slow progression.
Latest Trends
• Growing adoption of precision medicine and biomarker-driven treatment strategies.
• Expanding pipeline of monoclonal antibodies targeting fibrotic pathways.
• Use of artificial intelligence (AI) for early detection and imaging analysis.
• Increased collaborations between pharma companies and research institutes to accelerate innovation.
• Patient-centric initiatives, including telemedicine and digital health solutions, to improve disease monitoring.
Get Your Exclusive Offer with up to 10% Discount : https://exactitudeconsultancy.com/checkout/?currency=USD&type=single_user_license&report_id=71501
Competitive Landscape
Major Players
• Roche Holding AG
• Boehringer Ingelheim
• Bristol-Myers Squibb
• FibroGen Inc.
• Genentech
• Gilead Sciences
• Merck & Co.
• AstraZeneca
• Promedior Inc.
• MediciNova Inc.
• Cipla Limited
• Sun Pharmaceutical Industries Ltd.
• Zydus Lifesciences
Competition Summary
The pulmonary fibrosis market is moderately consolidated, with Roche and Boehringer Ingelheim dominating due to established antifibrotic drugs (pirfenidone and nintedanib). However, emerging biotech firms focusing on biologics, regenerative medicine, and gene therapy are intensifying competition. Strategic collaborations, mergers, and acquisitions are frequent, as companies aim to strengthen pipelines and expand geographic reach.
Conclusion
The pulmonary fibrosis market is entering a transformative decade. From a reliance on antifibrotic drugs to the development of advanced biologics and regenerative therapies, the treatment landscape is evolving rapidly. By 2034, the market is forecast to nearly double in size, driven by innovation, growing patient awareness, and supportive regulatory frameworks.
While challenges such as high treatment costs and late diagnosis persist, opportunities lie in precision medicine, AI-powered diagnostics, and expanding patient access programs. For pharmaceutical companies, research institutes, and healthcare providers, the pulmonary fibrosis market represents both a humanitarian need and a high-growth business opportunity.
Key Takeaways:
• The market is set to grow steadily through 2034, fueled by rising prevalence and therapeutic innovation.
• Antifibrotic drugs dominate today, but biologics and regenerative therapies are the future growth engines.
• Asia-Pacific will be the fastest-growing region, while North America and Europe remain established leaders.
• Strategic partnerships and continuous R&D investment are critical to competitive advantage.
This report is also available in the following languages : Japanese (肺線維症市場), Korean (폐섬유증 시장), Chinese (肺纤维化市场), French (Marché de la fibrose pulmonaire), German (Markt für Lungenfibrose), and Italian (Mercato della fibrosi polmonare), etc.
Request for a sample of this research report at (Use Corporate Mail ID for Quick Response) @ https://exactitudeconsultancy.com/reports/71501/pulmonary-fibrosis-market#request-a-sample
Our More Reports:
Lumbosacral Radicular Pain Market
https://exactitudeconsultancy.com/reports/71947/lumbosacral-radicular-pain-market
Memory Disorders Market
https://exactitudeconsultancy.com/reports/71948/memory-disorders-market
Multiple Organ Dysfunction Syndrome Market
https://exactitudeconsultancy.com/reports/71949/multiple-organ-dysfunction-syndrome-market
About Us
Exactitude Consultancy is a market research & consulting services firm which helps its client to address their most pressing strategic and business challenges. Our market research helps clients to address critical business challenges and also helps make optimized business decisions with our fact-based research insights, market intelligence, and accurate data.
https://bulletin.exactitudeconsultancy.com/
https://www.thehealthanalytics.com/
https://www.analytica.global/
https://www.marketintelligencedata.com/
https://www.marketinsightsreports.com/
https://exactitudeconsultancy.com/
Connect Us:
Irfan Tamboli
PHONE NUMBER +1 (704) 266-3234
EMAIL ADDRESS: sales@exactitudeconsultancy.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Pulmonary Fibrosis Market Projected to Reach USD 9.7 Billion by 2034 here
News-ID: 4170362 • Views: …
More Releases from Exactitude Consultancy
Airway Stent Market Projected to Reach USD 2.5 Billion by 2034
Airway stents play a vital role in maintaining airway patency in patients with obstructive pulmonary diseases, lung cancer, tracheobronchial strictures, and other airway complications. These medical devices help alleviate symptoms such as breathlessness and improve overall quality of life. With the rising incidence of chronic respiratory diseases and lung cancer globally, the demand for airway stents has been increasing steadily.
Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/71511
Recent advances…
Progressive Fibrosing Interstitial Lung Disease (PF-ILD) Patient Pool Analysis M …
Progressive fibrosing interstitial lung disease (PF-ILD) is an umbrella term describing a group of interstitial lung diseases that share common features such as lung scarring, decline in lung function, and poor prognosis. PF-ILD includes conditions such as idiopathic pulmonary fibrosis (IPF), connective tissue disease-associated ILD, chronic hypersensitivity pneumonitis, and unclassifiable ILD.
Download Full PDF Sample Copy of Market Report @https://exactitudeconsultancy.com/request-sample/71509
Over the past decade, PF-ILD has received increased attention due to its…
Malignant Pleural Effusion Market Projected to Reach USD 2.8 Billion by 2034
Malignant pleural effusion (MPE) is a severe complication of advanced cancers such as lung, breast, and ovarian cancers. Characterized by the accumulation of fluid in the pleural space due to malignancy, MPE causes significant morbidity, including breathlessness, chest pain, and reduced quality of life. Globally, MPE represents a growing healthcare challenge as cancer incidence rises and survival rates improve, leading to more patients experiencing secondary complications.
Download Full PDF Sample Copy…
Chronic Refractory Cough Market Projected to Reach USD 4.5 Billion by 2034
Chronic refractory cough (CRC) is a persistent cough lasting more than eight weeks that fails to respond to conventional treatment. It is a debilitating condition that significantly impacts quality of life, disrupting sleep, work productivity, and social interaction. Historically overlooked, CRC has recently become a central focus of pharmaceutical research, with new therapies emerging to address the unmet clinical need.
Download Full PDF Sample Copy of Market Report @
https://exactitudeconsultancy.com/request-sample/71505
Over the next…
More Releases for Pulmonary
Chronic Pulmonary Aspergillosis Drugs Market - Revitalizing Lungs: Revolutionary …
Newark, New Castle, USA - new report, titled Chronic Pulmonary Aspergillosis Drugs Market The report has been put together using primary and secondary research methodologies, which offer an accurate and precise understanding of the Chronic Pulmonary Aspergillosis Drugs market. Analysts have used a top-down and bottom-up approach to evaluate the segments and provide a fair assessment of their impact on the global Chronic Pulmonary Aspergillosis Drugs market. The report offers…
Global Pulmonary Embolism Market Size & Trends
According to a new market research report published by Global Market Estimates, the Global Pulmonary Embolism Market is exhibited at USD 1.59 billion in 2023 and is projected to surpass USD 3.15 billion in 2028, anticipated to grow at a CAGR of 8.4% from 2023 to 2028.
The rapid increase in the prevalence of cancer, increasing investment for healthcare infrastructure and rising research and development activities, high disposable income, rising demand…
Global Pulmonary Arterial Hypertension Market Size
According to a new market research report published by Global Market Estimates, the Global Pulmonary Arterial Hypertension Market is projected to grow at a CAGR of 5.2% from 2022 to 2027.
Congenital heart diseases and other ailments such as HIV infection, chronic liver disease (cirrhosis), and connective tissue disorders (scleroderma, lupus, and others) are fueling market expansion.
Browse 153 Market Data Tables and 113 Figures spread through 185 Pages and in-depth TOC…
New Study: Pulmonary Drugs Market Report
The pulmonary drugs market is expected to witness unprecedented growth in the near future, thanks to large number of approvals from the FDA. The FDA approved a large number of pulmonary drugs for major illnesses like small-cell lung cancer, tuberculosis, and pneumonia over the past few years. Additionally, newly approved drugs also treat newly found diseases like obstructive sleep apnea. These approvals are in line with the recent trend of…
Pulmonary Drugs Market Forecast till 2025
Pulmonary Drugs Market – Boon for Diseased Lungs
Pulmonary drugs can treat wide range of conditions, which are included within the ambit of pulmonary diseases such as pneumonia, allergic rhinitis, pulmonary hypertension, and others. . Pulmonary drugs provide medications for all types of pulmonary diseases, which is expected to fuel market growth in near future. The World Health Organization (WHO) states that most respiratory diseases are preventable and can be treated…
Pulmonary Drug Delivery Devices Market: Demand for Pulmonary Drug Delivery Devic …
This report on pulmonary drug delivery devices studies the current as well as future prospects of the market globally. The stakeholders of this report include companies and intermediaries engaged in the manufacture and commercialization of various pulmonary/respiratory drugs and/or drug-device combinations as well as new entrants planning to enter this market.
This report comprises an elaborate executive summary along with a market snapshot providing overall information of various segments and sub-segments…
